Fundraising

The Translation Gap

Why strong science loses the room. You're fluent in one language; the investor is listening in another. Here's the gap — and how to cross it.

What you tend to lead with
The science — how it works
What you built
The technical milestone
The risk you retired in the lab
→ Translate →
What they're actually buying
What it changes — and for whom
How big it could get
Whether the path to market is real
Why this team, why now

It's a translation problem, not a pitch problem. The work isn't saying it louder — it's saying it in the language the room is listening for.

The three moves

1

Lead with what it changes

Open with the outcome and who it's for — not the mechanism. The science is how you deliver the change; it isn't the opening line. If the first thing they hear is what's different in the world, they lean in.

2

Show the market and the path

Name how big it could get, and the realistic route from lab to product. Investors fund a believable path, not just a breakthrough. A roadmap with milestones tells them you've thought past the discovery.

3

Take the go-to-market risk off the table

They expect science risk — that's the bet they came to make. What scares them is everything after: the market, the team, the route to revenue. Reduce that, and the science risk becomes the only risk left — the one they actually want to take.

How to rebuild your pitch

01The change — what's different in the world if this works, and for whom
02The size — how big that change is
03The how — the science, now as the engine, said plainly
04The path — lab to product: the realistic roadmap and milestones
05The proof — the risk you've already retired
06The team & timing — why you, why now
07The ask — what you need, and what it unlocks
The one-line version

"We help [who] [achieve what outcome] using [the science, in plain words] — a [market] opportunity."

Lab language

"We've developed a novel platform for targeted gene activation with high specificity."

Investor language

"We can switch on the body's own defenses against [condition] — a [$X] market — and we've already shown the core science works in the lab."

The one rule

Translate, don't dumb down. The science still matters — it just isn't the headline. You're changing the order things are said, not hiding the depth.

The trap

Taking investor feedback verbatim into the negotiation. A VC asks for the moon because that's their job — hear the intent, not the literal terms, or you'll negotiate against yourself before you reach the table.

A CULT+MATH framework · Ipalibo Da-Wariboko · 2026
Start with DEOS OpenOr see the Decision Briefs

Use it with evidence

The framework is the read by feel. These measurements put sourced, dated numbers behind it. An AI assistant connected to CULT+MATH can run them for you, and can load this framework step by step with get_framework. Each run shows its price before anything is paid.

  1. Show the market: how crowded is the clinical pipeline for this condition?run_trial_pipeline
  2. Show the path: who is getting FDA clearance in this device category?run_device_clearances
  3. Is private money flowing into this industry?run_private_raises

Connect your agent

A real case

Answer · October 21, 2026What does a private equity firm actually check during due diligence?

Whatever can be verified — and the market has been reorganising around what cannot.

What the room checks once the science is believed: whatever can be verified.